About
Meet the key dealmakers who will launch your company to the next level and provide the well-needed infusion of capital and products
2009 has ushered in a new paradigm for Pharma/Biotech deal structuring. The current economic climate has altered both the approach and management of collaborative agreements and companies are now struggling to quickly adapt. For Pharma and Biotech companies to survive and thrive, it has become more essential than ever to not only cultivate relationships with the key industry players, but also to maximize the value of the deal and protect your assets by incorporating the evolving trends into current and future agreements.
Based on extensive research with industry professionals, ACI’s Advanced Forum on Structuring, Negotiating, and Managing Pharma/Biotech Collaborative Agreements was designed to provide you with the most up to date strategic analysis of current deal structuring while also delivering outstanding networking and business development opportunities to ensure you walk away with the contacts and intelligence you need to forge successful new alliances.
An exceptional faculty of diverse speakers will show you how to develop and cultivate lucrative relationships by sharing strategies on and solutions for:
- Capitalizing on shifting trends in the venture capital investment landscape
- Drafting critical termination terms
- Forging and protecting lucrative relationships with investors
- Negotiating partnerships with start-up innovators and government programs
- Contending with increased pressure from anxious investor’s seeking an immediate healthy return on their investment
- Redefining alliance management priorities
- Positioning your IP portfolio to increase your market power
- Negotiating milestones into the compensation structure
- Converting a licensing deal into an acquisition
Contents & Contributors
Predicting Future Trends & Developing Emerging Strategies in the Current Economic Environment
Yael Weiss, M.D., Ph.D., Director, Licensing and External Research, Merck and Co., Inc. (San Francisco, CA)
Anna Protopapas, Senior Vice President, Corporate Development and Strategy, Millennium, The Takeda Oncology Company (Cambridge, MA)
Kathleen Sereda Glaub, President, Plexxikon Inc. (Berkeley, CA)
Conducting Effective & Strategic Due Diligence
Mary Catherine DiNunzio, Head of Global Patent Alliances, H. Lundbeck A/S, (Copenhagen, Denmark)
Margaret M. Buck, MLS, JD, Patent Attorney, Lundbeck Research USA, Inc., (Paramus, NJ)
Jean Burke Fordis, Partner, Finnegan, Henderson, Farabow, Garrett & Dunner (Palo Alto, CA)
Stephen Johnson, Partner, Kirkland & Ellis LLP (San Francisco, CA)
Negotiating Essential Critical Terms to Maximize Profitability
Philip J. Honerkamp, Vice President, Deputy General Counsel, Jazz Pharmaceuticals Inc. (Palo Alto, CA)
James C. Snipes, Partner, Covington & Burling LLP (San Francisco, CA)
Jeffrey L. Wade, Executive Vice President and General Counsel, Lexicon Pharmaceuticals, Inc. (The Woodlands, TX)
Tanya Dobash Berlage, Partner and Chair, Life Sciences Practice Group, Saul Ewing LLP (Baltimore, MD)
Developing a Profitable Compensation Structure with Built-in Milestones to Maximize Value
Ron Myers, Vice President, Corporate Development and Legal Affairs, VLST Corp (Seattle, WA)
Cheni Kwok, Ph.D., CLP, Senior Vice President, Corporate Development, Poniard Pharmaceuticals (South San Francisco, CA)
Alex Scott, Vice President, Business Development, Eisai Inc. (Teaneck, NJ)
Structuring the Agreement with an Eye Towards M&A
Jeffrey C. Selman, Partner, Nixon Peabody LLP (Palo Alto, CA)
Creating and Implementing Critical Termination Provisions
Thomas E. Duley, Of Counsel, Morgan Lewis & Bockius LLP (San Francisco, CA)
(Former Senior Corporate Counsel and Head of Transactional Group for PDL BioPharma, Inc.)
Judith Ann Hasko, Partner, Latham & Watkins LLP (Menlo Park, CA)
Jonathan S. Dickstein, Partner, Morrison & Foerster LLP (San Francisco, CA)
Alliance Management: Establishing Governance Structures for Successful Collaborations
Mary Jo Struttmann, MBA, CA-AM, Senior Director, Alliance Management, Astellas US LLC (Deerfield, IL)
Andrew A. Paul, Senior Counsel, The Procter & Gamble Company, (Cincinnati, OH)
Crafting International Business Agreements for Calculated Growth and Sustainability
Stephen C. Ferruolo, Partner, Goodwin Procter LLP (San Diego, CA)
Maggie L. Wong, Associate, Goodwin Procter LLP (San Diego, CA)
Negotiating Collaborative Research Agreements with the U.S. Government and Academic Institutions
Claire T. Driscoll, Director, Technology Transfer Office, National Human Genome Research Institute (NHGRI), National Institutes of Health (NIH) (Bethesda, MD)
Brian Cummings, Executive Director, Technology Commercialization, University of Utah (Salt Lake City, UT)
David G. Schetter, Assistant Vice Chancellor for Research (Retired), University of California, Irvine (Irvine CA)
Bernadette M. Broccolo, Partner, McDermott Will & Emery, LLP (Chicago, IL)
Anticipating Future Technologies and Incorporating Terms into the Agreement to Protect Future Rights
Ralph A. Loren, Partner, Edwards Angell Palmer & Dodge, LLP (Boston, MA)
Publication Details